- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Aliso Viejo Today
By the People, for the People
RxSight Receives Average $9.78 Price Target from Brokerages
Analysts give mixed ratings on the medical technology company's stock.
Mar. 20, 2026 at 6:12am
Got story updates? Submit your updates here. ›
RxSight, Inc. (NASDAQ:RXST) has received a consensus 'Reduce' rating from 15 research firms covering the company, with an average 1-year price target of $9.78. Three analysts have a sell rating, 10 have a hold rating, and two have a buy rating on the stock.
Why it matters
RxSight's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction for cataract surgery patients. The mixed analyst ratings and average price target suggest uncertainty around the company's future performance and growth potential.
The details
The analysts' ratings and price targets for RxSight stock vary widely. Wolfe Research raised the stock to 'outperform', while Stifel Nicolaus cut its price target from $10 to $9. Needham & Company maintained a 'buy' rating with a $13 price target, and Morgan Stanley increased its price target from $9 to $10 while keeping an 'equal weight' rating.
- RxSight stock opened at $6.74 on Tuesday, March 20, 2026.
- The company has a 52-week low of $6.32 and a 52-week high of $27.13.
The players
RxSight, Inc.
A medical technology company focused on developing and commercializing advanced intraocular lens (IOL) systems for cataract surgery and lens replacement procedures.
Light Adjustable Lens (LAL)
RxSight's flagship product, designed to provide customized vision correction by allowing non-invasive post-operative adjustments using ultraviolet light.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident
The takeaway
The mixed analyst ratings and average price target for RxSight's stock suggest uncertainty around the company's future performance and growth potential, despite the innovative nature of its flagship Light Adjustable Lens product.
